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In areas of low malaria transmission, it is currently recommended that a single dose of primaquine (0.75 mg base/kg;
45 mg adult dose) be added to artemisinin combination treatment (ACT) in acute falciparum malaria to block malaria
transmission. Review of studies of transmission-blocking activity based on the infectivity of patients or volunteers to
anopheline mosquitoes, and of haemolytic toxicity in glucose 6-dehydrogenase (G6PD) deficient subjects, suggests that
a lower primaquine dose (0.25 mg base/kg) would be safer and equally effective. This lower dose could be deployed
together with ACTs without G6PD testing wherever use of a specific gametocytocide is indicated.Background
Primaquine is an important but underused anti-malarial
drug. The main limitation to the use of primaquine, either
for the radical cure of Plasmodium vivax or Plasmodium
ovale malaria, or as a gametocytocide in Plasmodium
falciparum malaria, is the risk of haemolysis in patients
who are glucose 6-phosphate dehydrogenase (G6PD) defi-
cient [1,2]. The prevalence of G6PD deficiency, an X-linked
trait, ranges from 5 to 20% in most malaria endemic areas
of Asia and Africa, and in some communities it is even
higher, so the total population at risk is very large [3]. Use
of primaquine as a gametocytocide has great potential to
reduce the transmission of falciparum malaria in low trans-
mission settings, and in particular to help contain the
spread of artemisinin resistant falciparum malaria in South-
East Asia. The World Health Organization has recom-
mended the addition of primaquine 0.75 mg base/kg (adult
dose 45 mg) to artemisinin combination treatment (ACT)
regimens for falciparum malaria in areas of low transmis-
sion [4], particularly in areas where artemisinin resistant
falciparum malaria is a threat, “when the risk for G6PD
deficiency is considered low or testing for deficiency is* Correspondence: nickw@tropmedres.ac
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reproduction in any medium, provided the oravailable” [5]. Unfortunately, testing for G6PDd is not
widely available in malaria endemic areas. Thus concerns
over the potential for dangerous iatrogenic haemolysis
have limited the use of primaquine. As a consequence
some countries deploy single dose primaquine as a game-
tocytocide, and some do not, and even when recom-
mended, primaquine is often not given.Transmission-blocking effects
Transmission of malaria requires that a feeding anopheline
vector mosquito ingests at least one male and one female
gametocyte in a blood meal, and that the subsequent
ookinete forms an oocyst in the wall of the mosquito
gut which later matures to liberate viable sporozoites
which migrate to populate the salivary glands. All the
effective anti-malarial drugs, in addition to killing the
asexual forms of all human malaria parasites, also kill early
developing gametocytes (stages 1 to 3) of P. falciparum.
Artemisinin derivatives reduce transmissibility substan-
tially in acute falciparum malaria, largely by killing
younger gametocytes (stages 1 to 4, and some early stage
5), but patients who have high numbers of infectious ma-
ture gametocytes at presentation may continue to transmit
despite receiving ACTs [6-14]. The 8-aminoquinolines kill
these mature infectious P. falciparum gametocytes rapidly
[15]. Reduction in gametocytaemia is relatively easy totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and













Figure 1 The rapid sterilizing effect of primaquine in
falciparum malaria; studies of mosquito infectivity following
anti-malarial treatments of falciparum malaria with
plasmoquine or primaquine in which oocyst assessments were
made in mosquitoes which fed 24 hours after drug
administration. Oocysts were assessed typically in 10–20
mosquitoes 6–7 days after feeding Medians (IQR) and ranges shown.
Gametocytaemia changed little in 24 hours (although it usually fell
rapidly thereafter) (left side) (N=51), whereas oocyst numbers fell
rapidly and were not found at all in the majority of mosquito
batches fed on treated patients (right side) (N=79). When the fed
mosquitoes were evaluated later sporozoites were correspondingly
absent) [15].
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trials, and has been the primary end-point in systematic
reviews of transmission-blocking interventions. However,
whilst there is a relationship between gametocyte densities
and transmissibility, this relationship varies substantially
between individuals [14-17]. In particular, patients with
acute P. falciparum infections may have high blood
densities of young stage 5 gametocytes which are not
infectious. Furthermore drug effects on transmissibility
precede effects on gametocytaemia, probably because
of the lag between gametocyte killing and gametocyte
clearance, so the transmission-blocking effect may be
underestimated [15]. Dose–response assessment, there-
fore, requires direct assessment of the infectivity of
patient's blood to anopheline mosquitoes. This is diffi-
cult, and in recent years has seldom been undertaken.
The 8-aminoquinoline anti-malarial plasmoquine, the
predecessor of primaquine, was discovered in 1924 [18,19].
Within two years plasmoquine had been shown to clear
gametocytaemia in falciparum malaria [20], and between
1927 and 1929, in Panama, was shown to reduce rapidly
the infectivity of P. falciparum to anopheline mosquitoes
[21,22]. Even in these first studies it was evident that the
transmission-blocking effect (assessed as reduction in
mosquito oocyst counts) preceded the effects on game-
tocytaemia (Figure 1). Plasmoquine was commonly pre-
scribed at adult doses of 60mg yet doses as low as
10mg provided rapid and potent transmission-blocking
activity [21-25]. Primaquine replaced plasmoquine in the
early 1950s as it was safer and more effective [15,26]. In
clinical studies primaquine was three times more active
against pre-erythrocytic stages, four to six times better in
terms of radical curative activity against vivax malaria,
and it was half as toxic. The transmission-blocking activ-
ities of the two drugs were never compared. In 1959,
Martin Young reported on two gametocytaemic adult
patients who received only 3 mg per day of primaquine
alone and were non-infectious to anophelines within three
and five days, respectively, of starting this treatment [27].
These observations suggested that doses much lower than
the currently recommended adult gametocytocide dose of
45 mg would still be effective.
Individual data are available on 158 individual gameto-
cytaemic subjects from studies conducted in different
locations with different vectors and different drug expo-
sures spanning approximately 80 years in which infectivity
was assessed both by oocyst and sporozoite production 24
and 48 hours after drug exposure [15,28]. Of these 31 sub-
jects received plasmoquine (before 1950) and 127 received
primaquine (78 in hitherto unpublished studies conducted
by Li Guoqiao and Chen Peiquan in Xuan Loc Hospital,
Dong Nai Province, Vietnam, 1993–1996, and Kampong
Speu Province Hospital, Cambodia, 2003–2004). In 65
of the patients primaquine was given together with anartemisinin derivative. These studies show clearly that
both plasmoquine and primaquine rapidly and potently
reduce the infectivity of P. falciparum. Primaquine
increases the rate of gametocyte clearance but there is a
lag phase of >24 hours before clearance accelerates. The
effects on transmissibility assessed from mosquito oocyst
numbers, and consequent sporozoite numbers and viabil-
ity, occur much more rapidly than the effects on gam-
etocyte densities (Figure 1). This suggests that most or
all the gametocytes counted in blood films in the days
following primaquine administration are dying or dead
[15]. In these artificial infection experiments, the sub-
jects selected for study commonly had high gametocy-
taemias, at the upper end of the distribution of
gametocyte densities encountered in natural infections,
and were highly infectious. This provided sufficient
numbers for statistical assessment but it resulted in
heavy mosquito infections (often > 30 oocysts per gut)
which are rarely found in trapped wild anopheline
vectors. Drug effects on gametocyte viability are continu-
ous, but the final effect on transmission to a mosquito is
binary – it is either infected or it is not, and only one suc-
cessful oocyst is all that is necessary for a mosquito to be
potentially infective. For example, if there were 1,000
viable gametocytes/μL of blood, a reduction by 99% still
leaves 10 gametocytes/μL - which may still be infectious;
whereas if there were 10 gametocytes/μL initially, then a
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very unlikely to infect [15].
Compared to the volunteer studies, gametocyte densities
in malaria infected individuals under natural conditions
are generally much lower, with the majority being below
the limit of routine microscopy detection [14,29]. Infected
wild anopheline mosquito vectors when examined have
correspondingly less intense infections (median 2 oocysts
per gut) [30]. Thus these artificial infection studies in
which man to mosquito infectivity was optimized tend
to underestimate transmission-blocking drug effects at a
population level. In the individual transmission-blocking
assessments, nearly all adult subjects (102/108; 94.4%;
95% confidence interval 90.1 to 98.8%) who received
primaquine at a dose ≥ 0.13 mg base/kg (adult dose
≥7.5 mg) had their infection sterilized within 48 hours
after taking the drug. Oocyst (Figures 2 A and 2 B) and
sporozoite (Figures 3 A and 3 B) responses were simi-
lar. Furthermore, concomitant treatment with artemisi-
nin derivatives augmented the transmission-blocking
effect significantly (Figures 2 A, 2 B, 3 A, 3 B). These
dose–response assessments suggest a primaquine ED90
of approximately 0.06 mg base/kg given together with
an artemisinin derivative, and 0.09 mg/kg without. This
pooled analysis supports use of a dose lower than 0.75 mg
base/kg (45 mg base adult dose) in transmission reduction
strategies combined with an ACT.
Safety
Primaquine is safe and generally well tolerated (with
food) in G6PD normal subjects, although adult doses
over 30 mg are associated with an increased incidence
of abdominal discomfort [31]. On the other hand, in
subjects who are G6PD deficient primaquine predic-
tably causes acute haemolytic anaemia [32-34]. OverFigure 2 Dose–response relationships for primaquine in reducing the
mosquitoes. Vertical axis shows the proportion of fed anopheline mosquit
[15,28]. Left: Oocyst formation (proportion of patients who were still infecti
dose, Right : Oocyst formation from blood sampled 48 hours after primaqu
green, and with a non-artemisinin derivative or no anti-malarial is shown in
the circle is proportional to the number of subjects in each group (shown180 different G6PD deficiency alleles have been identified
[1,2]. Most of the mutations result in reduced enzyme
stability: as red cells age their G6PD activity declines
much more rapidly than in G6PD normal red cells,
resulting in a marked reduction in the average enzyme
concentration in the total population of circulating red
cells. With many common G6PD deficiency alleles the
mean enzyme concentration is less than 15% of that in
normal red cells. G6PD deficient red cells are less able to
regenerate NADPH, which is essential for maintenance of
their principle anti-oxidant defences, particularly reduced
glutathione, and for the function of catalase. Fava beans
(which contain oxidant glucosides) and oxidant drugs
(including sulphones and 8-aminoquinolines) produce
predictable dose-dependent haemolysis in G6PD deficient
subjects. Anaemia develops rapidly and in severe cases
there may be nausea, vomiting, agitation, abdominal or
loin pain, passage of dark coloured or black urine, and
the patient may become jaundiced. Haemolysis can be
life-threatening as a result of the anaemia itself, when it is
very severe, or because massive intravascular haemolysis
with haemoglobinuria may precipitate acute renal failure
(more likely in adults). The peripheral blood film shows
marked poikilocytosis, and characteristic abnormal red
cells called hemighosts; Heinz bodies can be seen after
appropriate staining. Methaemoglobinaemia also occurs:
its mechanism is different, as it is not limited to G6PD
deficient persons.
The severity of drug-induced acute haemolytic an-
aemia (AHA) in G6PD deficient persons depends on
several factors, the most important of which are: (a)
drug dosage, (b) the genotypic combinations at the
G6PD locus (which are different in males versus
females), and (c) the allelic variants of the G6PD
gene.infectivity of P. falciparum infected subjects to anopheline
oes which were infected. Pooled data from all studies conducted
ous to mosquitoes) from blood sampled 24 hours after primaquine
ine dose. Primaquine given with an artemisinin derivative is shown in
red. In these studies 29 patients received no primaquine. The size of
within).
Figure 3 Dose–response relationships for primaquine in reducing infectivity to anopheline mosquitoes as in Figure 2, assessing
sporozoite formation. Left: Sporozoite formation assessed from blood sampled 24 hours after primaquine dose, Right: Sporozoite formation
assessed from blood sampled 48 hours after primaquine dose. Numbers are not exactly the same as in Figure 2 because sporozoites were not
assessed in all studies.
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Figure 4 Studies of 51Cr labelled red cell survival in healthy
adult hemizygous male volunteers with the A-variant of G6PD
deficiency exposed to different dose regimens of primaquine in
studies conducted by the University of Chicago-Army Medical
Research Unit at the Illinois State penitentiary (Stateville) from
1950 to 1962. Daily doses are shown within the range of red cell
survivals that resulted. Daily administration of 45 mg base
primaquine was considered to result in “dangerous haemolytic
anaemia”, daily administration of 30 mg resulted in severe
haemolysis and acute anaemia, and daily administration of 15 mg
resulted in moderate haemolysis and mild anaemia [36].
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Experimental studies with human volunteers
Primaquine is given once when used as a P. falciparum
gametocytocide, but it is given for 14 days for the radical
cure of P. vivax and P. ovale malaria. When primaquine
was administered daily to ‘primaquine-sensitive’ men
(subsequently shown to have the A- variant of G6PD
deficiency), there was brisk haemolysis with haemo-
globinuria [31,32,35-37]. This haemolytic process was
dose-dependent (Figure 4): haemoglobin fell by about
one-third with 30 mg base primaquine daily, but by
only ~15% with 15 mg primaquine daily. In contrast,
a once weekly dose, even as high as 60 mg, had
much less effect (see Figure 5). Primaquine is elimi-
nated rapidly with a terminal elimination half-life of
approximately five hours in patients with acute mal-
aria, [38], so if primaquine is stopped the drug and
its reactive metabolites are cleared quickly. This lim-
its the degree of haemolysis. These dose–response
observations in subjects with the African A- G6PD
variant together with experience in large numbers of
soldiers (see below) led to recommendation of a
modified radical curative regimen in P. vivax and P.
ovale malaria of 0.75 mg base/kg once weekly for
eight weeks in patients with the A- type of G6PD
deficiency [4,35].
Clinical case reports and series
When primaquine was first introduced in 1951 it was
given in a radical curative regimen of 15 mg base per
day for two weeks to prevent P. vivax relapse in some
250,000 US troops returning from the Korean war dur-
ing their trans-Pacific sea voyage. Of these 10% were
African-American soldiers [35]. It was stated that “there
were very few serious adverse effects”, although later
studies showed that in “primaquine sensitive” indivi-
duals the haematocrit often fell by one fifth! Weeklyprimaquine 45 mg (combined with chloroquine) was
also used extensively in American soldiers in the Vietnam
war. The net result of these clinical and experimental stud-
ies and the field experience was that a 0.75 mg base/kg
(adult dose 45 mg) was recommended as the single game-
tocytocidal dose of primaquine in P. falciparum malaria.
No deaths have been reported following a single dose
of primaquine [39]. Primaquine has been also used in
the mass treatment of millions of patients in continuous
regimens [40,41], mainly at the original adult dose
equivalent of 15 mg base per day, without G6PD testing.
All of the 13 attributable deaths reported (11 from severe
Figure 5 Once weekly administration of primaquine 45 mg base for 8 weeks to healthy adult hemizygous male volunteers with the
A- variant of G6PD deficiency resulted in less anaemia than daily administration of 15 mg for two weeks [35].
White et al. Malaria Journal 2012, 11:418 Page 5 of 9
http://www.malariajournal.com/content/11/1/418haemolysis) resulted from repeated doses of primaquine
[38]. The estimated risk of severe adverse effects (i.e. AHA)
from this mass drug administration and routine treatment
experience was approximately three per million. However,
in prospective studies which focussed on safety, the esti-
mated risk of severe adverse effects (severe anaemia,
haemoglobinuric renal failure) was three orders of magni-
tude higher: 3.9 per thousand [39]. Although this figure
still sounds reassuring at a population level it is import-
ant to emphasize that this risk is borne entirely by the
sub-group of individuals who are G6PD deficient, all of
whom will haemolyse with currently recommended
primaquine doses to an extent determined by the sever-
ity of their enzyme deficiency [42,43]. These data also
underscore the important difference in the safety of a
single dose of primaquine versus continuous administra-
tion. The single 0.75 mg base/kg dose has generally been
regarded as relatively safe [4,31] although in Vanuatu,
where this dose of primaquine was introduced as a game-
tocytocide with the treatment of P falciparum malaria,
over a period of two years seven cases of acute haemo-
globinuria were observed with severe anaemia in G6PD
deficient men and the policy was discontinued [44].
Genotypic combinations at the G6PD locus
G6PD is X-linked. Males have only one G6PD allele
(they are either normal or deficient hemizygotes),
whereas females have two (so they can be homozygous
G6PD normal, or homozygous G6PD deficient, or het-
erozygous). Hemizygous males and homozygous females
have full expression of G6PD deficiency: the level of
G6PD activity in their mature red cells is nearly always
≤15% of normal values. Heterozygous females usually
have only partial deficiency, and they have been referred
to as having ‘intermediate’ deficiency. Among X-linked
genes, G6PD belongs to the majority that are subject to
X chromosome inactivation. Therefore ‘intermediate’
deficiency does not mean that each red cell has anintermediate level of G6PD: rather, it is a cumulative
average, whereby some red cells have normal levels of
G6PD whereas others are G6PD deficient. Moreover,
because X-inactivation is a random event which takes
place early in embryonic life (Lyonization), the result-
ing proportions of these two cell types are very va-
riable. The severity of oxidant haemolysis in female
heterozygotes will, therefore, vary from that in hemi-
zygous males to that in G6PD normal persons (i.e. rela-
tively little or no haemolysis) [42]. Unfortunately, in some
studies heterozygous females have been labelled as G6PD
deficient, and grouped together with G6PD deficient hemi-
zygous males, which has compromised assessments of the
clinical severity of acute haemolytic anaemia (AHA). The
fall in haemoglobin in heterozygote females will be, on
average, one-half of that seen in hemizygous male and
homozygous females. From a clinical standpoint, heterozy-
gotes with >70% G6PD normal red cells (i.e. < 30% G6PD
deficient red cells) are unlikely to develop severe AHA.
Allelic variants of the G6PD gene
Many of the >180 G6PD deficiency alleles known are
polymorphic, and are common in populations in the
tropics (Figure 6). The degree of G6PD deficiency is an
individual characteristic of each G6PD variant. For ex-
ample the modal value of red cell G6PD activity is
about 5% of normal for G6PD Mediterranean, whereas
it is 13% for G6PD A-. This difference has clinical
implications. In experimental studies carried out on
otherwise normal subjects with G6PD Mediterranean the
severity of AHA following primaquine was considerably
greater [45,46] than with G6PD A- (see under (i) above).
However, for both G6PD variants there is a sufficiently
wide variation around the modal value of G6PD activity
for the two distributions to overlap. Correspondingly,
there is also overlap in the severity of the clinical manifes-
tations. Many of the G6PD variants that are polymorphic
in South-East Asia (e.g. G6PD Mahidol, G6PD Viangchan,
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between that of G6PD Mediterranean and G6PD A-,
which suggests that their haemolytic risk occupies a simi-
lar position.
Naturally the clinical consequences of drug-induced
AHA depend to a considerable extent on clinical status
when the drug is administered, and particularly on pre-
existing anaemia [34,42,43,46,48]. Thus, the risk is mark-
edly different in healthy adults, such as those who were
given primaquine experimentally, or soldiers who were
given primaquine as anti-malarial prophylaxis, compared
to children with acute malaria in endemic areas who are
often already anaemic.
Although more data are needed on the dose–response
relationship for haemolysis following single dose prima-
quine in G6PD deficient subjects with different G6PD var-
iants, the evidence available to date suggests that the risk
of serious haemolysis is low. The data on the transmission-
blocking dose–response reviewed here suggest that max-
imal responses are obtained with doses substantially lower
than 0.45 mg base/kg, particularly if primaquine is used
with an ACT. Thus, without attenuating the transmission
blocking effect, in G6PD deficient individuals the risks of
haemolysis could be reduced significantly by reducing the
dose from 0.75 to 0.25 mg base/kg.
Discussion
Incorporating a gametocytocide in a standard course of
anti-malarial treatment may benefit the local community
in terms of reduced incidence of malaria, and the global
community by preventing the spread of resistant malaria
parasites [5,17]. In areas of high or moderate transmissionFigure 6 Global distribution of polymorphic G6PD deficiency mutantsintensity this benefit is likely to be modest, because there
is considerable redundancy in the transmission reservoir
from asymptomatic individuals. On the other hand, in
areas of low transmission every treated infection is a po-
tentially important source of transmission, as well as of
potential selection of drug resistant parasites. The degree
of benefit depends on (i) the proportion of transmission
derived from asymptomatic infections (ii) the proportion
of symptomatic patients who receive gametocytocidal
treatment (“coverage”) and (iii) on how early this is given
in the course of a symptomatic infection (“access”). A
single dose of primaquine (0.5 to 0.75 mg base/kg) is
deployed as a P. falciparum gametocytocide by many coun-
tries, and is not deployed by others with similar epidemio-
logical characteristics. Primaquine is practically never used
in the private sector, which in some countries is the major
provider of anti-malarial drugs. Although G6PD testing is
encouraged, in reality it is usually not carried out. In the
epicentre of artemisinin resistance in South-East Asia
[49,50], where transmission-blocking strategies can play an
important role in slowing the spread of resistant parasites
[5], neither Cambodia nor Laos currently deploy prima-
quine as a gametocytocide because of safety concerns.
The wide disparity between the estimates of the fre-
quency of primaquine induced AHA, derived mainly from
passive reporting, versus the regular occurrence of AHA in
prospectively studied G6PD deficient subjects is not sur-
prising. Both anaemia and haemoglobinuria may go
unnoticed or unreported, and the frequency of adverse
events in G6PD deficient subjects is diluted by the
much larger numbers of G6PD normal subjects in whom
AHA does not occur. The importance of the different[47].
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though the degree of G6PD enzyme deficiency is less
severe with G6PD A- than with most other alleles,
AHA still occurs when primaquine is administered to
individuals with this variant. With most other variants
AHA can be expected to be more severe, and in the
case of G6PD Mediterranean this is indeed the case
[45]. On the other hand, clinical and experimental evi-
dence shows that the haemolytic effect of a single dose
of primaquine is considerably lower than with continu-
ous administration [35]. The available data on haemo-
lytic risks and transmission-blocking dose–response
reviewed here suggest that a dose of 0.25 mg base/kg
(15 mg adult dose) of primaquine in combination with
an ACT would retain the transmission blocking effect
of the currently recommended 0.75 mg/kg dose, whilst
reducing substantially the severity of haemolysis in
G6PD deficient subjects. This suggests that a 0.25 mg
base/kg could be deployed without G6PD testing wher-
ever use of a specific gametocytocide is indicated, a
recommendation recently made by the World Health
Organisation [51]. Meanwhile G6PD testing is still neces-
sary for the seven to 14 day regimens needed for radical
cure of vivax or ovale malaria, and so testing still needs
to be made much more widely available (Table 1).
A recent Cochrane systematic review [52], which con-
centrated primarily on studies reporting gametocyte car-
riage rather than infectivity assessments, concluded that
“primaquine should not be added to routine treatment
of P. falciparum malaria with ACT until
1) it has been demonstrated that reducing infectivity of
treated people in a variety of endemic situations
reduces transmission on a community basis;
2) further research is done on safety and on adverse
haematological effects for both G6PD normal and
G6PD deficient subjects;
3) more is understood about the proportion of
gametocyte carriers who present to receive treatment
in a given population and time period
4) the cost of the policy balanced against the potential
benefit is explored. In any case, patients should be
screened for G6PD deficiency and those with variants
predisposing to haemolysis should not be given PQ.”Table 1 Recent WHO recommendation for “low dose”
primaquine as a P. falciparum gametocytocide [51]
In: (1) areas threatened by artemisinin resistance where single dose
primaquine as a gametocytocide for P. falciparum malaria is not being
implemented, and (2) elimination areas which have not yet adopted
primaquine as a gametocytocide for P. falciparum malaria: A single 0.25
mg base/kg primaquine dose should be given to all patients with
parasitologically- confirmed P. falciparum malaria on the first day of
treatment in addition to an ACT, except for pregnant women and
infants <1 year of age.These are large and difficult questions which would
certainly take many years to answer if the detailed prospect-
ive clinical and epidemiological studies requested were
undertaken. Whilst the Cochrane review [52] probably
underestimated the transmission-blocking effect of prima-
quine by concentrating on gametocytaemia, it is true that
there have been few trials providing evidence for commu-
nity benefit. It is difficult to assess any single malaria con-
trol community intervention in isolation, and, even if such
large cluster randomized trials were conducted, undoubt-
edly there would still be issues of generalizability. Cur-
rently however, there is an urgency to counter the spread
of artemisinin resistance; and a number of countries are
in pre-elimination and elimination phases so time is a
very important commodity. The extensive data reviewed
in brief here indicate that the safety of primaquine can be
improved without loss of transmission-blocking efficacy.
Primaquine is not being recommended as a gametocyto-
cide in moderate or high transmission settings. While
small foci of higher transmission with asymptomatic
carriage are also features of low seasonal transmission
settings, and more information on their epidemiology is
needed, it is not clear how understanding more about
them can be generalized to a treatment recommendation,
particularly as there is such a diversity of epidemiological
settings. Finally, any cost-benefit analysis must take into
account whether control or elimination is the goal: in this
respect, costs would be reduced and ease of deployment
considerably enhanced if point of care G6PD testing was
not necessary. In addition, there is also a critical cost, in
terms of morbidity and mortality, of waiting years for
more information and missing opportunities for decisive
action [53].
Prospective studies should be conducted to confirm the
safety of a single dose of primaquine 0.25 mg base/kg as a
gametocytocide together with ACT in individuals with
G6PD deficiency, and to assess transmission blocking activ-
ity dose–response relationships in different geographic
areas, particularly in the context of artemisinin resistant fal-
ciparum malaria. In the meantime, based on the data
reviewed above, there is sufficient evidence on safety and
efficacy to support widescale deployment of a single dose of
primaquine 0.25 mg base/kg as a gametocytocide without
G6PD testing now where it is needed.
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